What is the half-life of Tesamorelin?

Tesamorelin has a half-life of 26-38 minutes, which is why it's typically administered once daily for optimal therapeutic effect.

How do I reconstitute Tesamorelin?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Growth Hormone

Phase 3

Tesamorelin

Also known as: Egrifta, TH9507

Overview

Key Facts

Primary Goal: An FDA-approved GHRH analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy

An FDA-approved GHRH analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is a 44-amino acid peptide with a trans-3-hexenoic acid modification that enhances stability. Half-Life 26-38 minutes Typical Dose 1000–2000 mcg Frequency once daily Cycle Length 26 weeks (per FDA labeling), ongoing as prescribed

Dosing Information

Half-Life

26-38 minutes

Typical Dose

1000–2000 mcg

Frequency

once daily

Cycle Length

26 weeks (per FDA labeling), ongoing as prescribed

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy. Phase III trials demonstrated an average 15-18% reduction in visceral adipose tissue over 26 weeks. More recent research has explored its potential cognitive benefits, with a 2020 study showing improvements in executive function and verbal memory in adults at risk for Alzheimer's disease.